HUP0401514A3 - Pharmaceutical compositions for the treatment of asthma - Google Patents

Pharmaceutical compositions for the treatment of asthma

Info

Publication number
HUP0401514A3
HUP0401514A3 HU0401514A HUP0401514A HUP0401514A3 HU P0401514 A3 HUP0401514 A3 HU P0401514A3 HU 0401514 A HU0401514 A HU 0401514A HU P0401514 A HUP0401514 A HU P0401514A HU P0401514 A3 HUP0401514 A3 HU P0401514A3
Authority
HU
Hungary
Prior art keywords
asthma
treatment
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HU0401514A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0401514(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HUP0401514A2 publication Critical patent/HUP0401514A2/hu
Publication of HUP0401514A3 publication Critical patent/HUP0401514A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0401514A 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma HUP0401514A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
PCT/US2002/027336 WO2003020253A2 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Publications (2)

Publication Number Publication Date
HUP0401514A2 HUP0401514A2 (hu) 2004-12-28
HUP0401514A3 true HUP0401514A3 (en) 2012-08-28

Family

ID=23224164

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401514A HUP0401514A3 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Country Status (26)

Country Link
US (3) US20030114428A1 (enExample)
EP (3) EP1420759B1 (enExample)
JP (3) JP2005502675A (enExample)
KR (1) KR100970531B1 (enExample)
CN (2) CN101856362A (enExample)
AR (1) AR036358A1 (enExample)
AT (2) ATE503461T1 (enExample)
AU (1) AU2002313828B2 (enExample)
BR (1) BR0212089A (enExample)
CA (1) CA2457926A1 (enExample)
CO (1) CO5560551A2 (enExample)
CY (2) CY1109212T1 (enExample)
DE (2) DE60239648D1 (enExample)
DK (2) DK2092935T3 (enExample)
ES (3) ES2325316T3 (enExample)
HU (1) HUP0401514A3 (enExample)
MX (1) MXPA04001875A (enExample)
NO (1) NO20041277L (enExample)
NZ (1) NZ530987A (enExample)
PE (1) PE20030390A1 (enExample)
PL (1) PL209640B1 (enExample)
PT (2) PT1420759E (enExample)
SI (2) SI1420759T1 (enExample)
TW (1) TWI324934B (enExample)
WO (1) WO2003020253A2 (enExample)
ZA (1) ZA200401419B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
EP1542753B1 (en) * 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
AU2003265639A1 (en) * 2002-08-27 2004-03-19 Schering Corporation Process for producing metered dose inhaler formulations
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
AU2004285447A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical compositions
ES2426957T3 (es) * 2004-01-21 2013-10-28 Merck Sharp & Dohme Corp. Procedimiento de tratamiento de rinosinusitis aguda
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
CA2581999C (en) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
WO2008097233A1 (en) * 2007-02-09 2008-08-14 Schering Corporation Stable pharmaceutical drug aerosols
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
JP2011509936A (ja) * 2008-01-10 2011-03-31 シェーリング コーポレイション 吸入薬物製品、システムおよび使用
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2010112358A2 (de) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Verfahren zur beschichtung einer oberfläche eines bauteils
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) * 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064164A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
ES2487634T3 (es) * 2009-12-07 2014-08-22 Raptor Therapeutics Inc. Formulaciones de 4-metilpirazol
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
HUE042556T2 (hu) 2011-10-11 2019-07-29 Chiesi Farm Spa Zsírsavval bevont béta-agonista kristályos mikrorészecskéi
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
KR102443737B1 (ko) 2014-05-07 2022-09-19 베링거 인겔하임 인터내셔날 게엠베하 컨테이너, 분무기 및 사용 방법
EP3928818B1 (en) 2014-05-07 2023-02-01 Boehringer Ingelheim International GmbH Nebulizer and container
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
CN106573082B (zh) 2014-06-30 2020-01-17 普罗沃锐斯科学有限公司 用于确定药物的递送剂量的量和均匀性的采样装置及相关方法
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
ES2866175T3 (es) 2015-12-04 2021-10-19 Mexichem Fluor Sa De Cv Composición farmacéutica
WO2017156287A1 (en) 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN116583316A (zh) 2020-10-15 2023-08-11 普罗沃锐斯科学有限公司 用于吸入器测试的系统和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1992022288A1 (en) * 1991-06-10 1992-12-23 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
ATE202936T1 (de) * 1996-08-29 2001-07-15 Schering Corp Chlorfluorkohlenwasserstoff freie aerosol- arzneizubereitungen enthaltend mometasonfuroat
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
EP1133301A1 (en) * 1998-11-26 2001-09-19 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
CN1406124A (zh) * 2000-01-20 2003-03-26 巴斯利尔药物股份公司 鼻给药的环肽组合物
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
PL368897A1 (en) 2005-04-04
JP2005502675A (ja) 2005-01-27
JP2009185075A (ja) 2009-08-20
CA2457926A1 (en) 2003-03-13
US20100143269A1 (en) 2010-06-10
AU2002313828B2 (en) 2005-09-08
ATE430555T1 (de) 2009-05-15
KR20040031002A (ko) 2004-04-09
DK1420759T3 (da) 2009-08-03
HK1060972A1 (en) 2004-09-03
ES2325316T3 (es) 2009-09-01
CN1649568B (zh) 2010-10-27
JP2010138184A (ja) 2010-06-24
PT1420759E (pt) 2009-06-30
ES2389480T3 (es) 2012-10-26
MXPA04001875A (es) 2004-06-15
CY1109212T1 (el) 2014-07-02
NZ530987A (en) 2006-08-31
EP1420759B1 (en) 2009-05-06
BR0212089A (pt) 2004-08-03
PT2092935E (pt) 2011-05-31
SI1420759T1 (sl) 2009-10-31
KR100970531B1 (ko) 2010-07-16
EP2092935B1 (en) 2011-03-30
WO2003020253A3 (en) 2003-05-22
ATE503461T1 (de) 2011-04-15
US20030114428A1 (en) 2003-06-19
ZA200401419B (en) 2005-01-26
CN1649568A (zh) 2005-08-03
DE60232251D1 (de) 2009-06-18
EP2092935A1 (en) 2009-08-26
DK2092935T3 (da) 2011-07-18
CY1111726T1 (el) 2015-10-07
SI2092935T1 (sl) 2011-07-29
HUP0401514A2 (hu) 2004-12-28
US20050147565A1 (en) 2005-07-07
DE60239648D1 (de) 2011-05-12
EP2319494A1 (en) 2011-05-11
HK1128428A1 (en) 2009-10-30
TWI324934B (en) 2010-05-21
WO2003020253A2 (en) 2003-03-13
EP1420759A2 (en) 2004-05-26
JP5170789B2 (ja) 2013-03-27
AR036358A1 (es) 2004-09-01
HK1151987A1 (en) 2012-02-17
PE20030390A1 (es) 2003-04-24
ES2361805T3 (es) 2011-06-22
CN101856362A (zh) 2010-10-13
NO20041277L (no) 2004-03-26
EP2319494B1 (en) 2012-06-13
CO5560551A2 (es) 2005-09-30
PL209640B1 (pl) 2011-09-30

Similar Documents

Publication Publication Date Title
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
HUP0200493A3 (en) Pharmaceutical compositions comprising sulphonyl-amino-carbonyl derivatives for the treatment of nuclear factor-kappa b mediated diseases
IL160187A0 (en) Aerosolized decongestants for the treatment of sinusitis
HUP0600781A2 (en) Compounds for the treatment of metabolic disorders and pharmaceutical compositions containing them
EP1407785A4 (en) MEDICAL COMPOSITIONS
IL161070A0 (en) Compositions for the treatment of infectious diseases
GB0111597D0 (en) Pharmaceutical compositions
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
IL143106A (en) Process for the preparation of diphenylmethylthioacetamide
AU2002365093A8 (en) Therapeutic compositions
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
HUP0401042A3 (en) Pharmaceutical compositions suitable for treating primary insomnia
GB0104752D0 (en) Pharmaceutical compositions
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
GB0109428D0 (en) Therapeutic compositions
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
HUP0303025A3 (en) Process for the preparation of arylethanoldiamines
HUP0200253A3 (en) Pharmaceutical compositions for combination therapy
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB2382302B (en) Pharmaceutical compositions
HU0104528D0 (en) Process for the preparation and use of biocide compositions
GB0123063D0 (en) Compositions for therapy
HUP0103049A3 (en) Use of fluexetine for preparation of pharmaceutical compositions

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORPORATION, US

FD9A Lapse of provisional protection due to non-payment of fees